Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis

Steven B. Zeliadt, David F. Penson, Peter C. Albertsen, John Concato, Ruth Etzioni

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND. The goals of the current study were to describe patterns of prostate specific antigen (PSA) surveillance for prostate carcinoma progression in a community-based cohort of patients and to identify independent clinical and socio-demographic factors that predict the frequency of surveillance. METHODS. Patients diagnosed with localized prostate carcinoma from October 1, 1991 to December 31, 1992 in New Haven and Hartford, Connecticut, were identified. Data were collected through standardized outpatient medical record review. Multivariate statistical methods were used to determine the factors that independently predicted the frequency of surveillance. RESULTS. Six hundred fifty-eight men with localized prostate carcinoma were included in the cohort. Forty-five percent of all patients were tested at least once annually, and 69% were tested at least once every 2 years. Multivariate models indicated that African American men were half as likely as Caucasian men to receive annual testing (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.24-0.97). Men diagnosed at age 70 years or older were 38% less likely to have annual testing than men diagnosed between the ages of 65 and 69 (OR, 0.62; 95% CI, 0.41-0.94). A higher Gleason score and PSA at presentation also were associated independently with higher rates of annual PSA surveillance. CONCLUSIONS. Postdiagnosis PSA surveillance is common, although not universal. African American men were at significantly greater risk for receiving less frequent testing compared with Caucasian men. This disparity in access to care may explain, in part, previously observed racial differences in survival in prostate carcinoma. Further research is needed to identify the reasons for the racial disparity in PSA surveillance and to design interventions to lessen these differences.

Original languageEnglish (US)
Pages (from-to)496-503
Number of pages8
JournalCancer
Volume98
Issue number3
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostate
Carcinoma
African Americans
Odds Ratio
Confidence Intervals
Neoplasm Grading
Antigen Presentation
Medical Records
Outpatients
Demography
Survival
Research

Keywords

  • Prostate carcinoma
  • Prostate specific antigen testing
  • Race
  • Recurrence
  • Surveillance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zeliadt, S. B., Penson, D. F., Albertsen, P. C., Concato, J., & Etzioni, R. (2003). Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer, 98(3), 496-503. https://doi.org/10.1002/cncr.11492

Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. / Zeliadt, Steven B.; Penson, David F.; Albertsen, Peter C.; Concato, John; Etzioni, Ruth.

In: Cancer, Vol. 98, No. 3, 01.08.2003, p. 496-503.

Research output: Contribution to journalArticle

Zeliadt, SB, Penson, DF, Albertsen, PC, Concato, J & Etzioni, R 2003, 'Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis', Cancer, vol. 98, no. 3, pp. 496-503. https://doi.org/10.1002/cncr.11492
Zeliadt, Steven B. ; Penson, David F. ; Albertsen, Peter C. ; Concato, John ; Etzioni, Ruth. / Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. In: Cancer. 2003 ; Vol. 98, No. 3. pp. 496-503.
@article{fedb849719684221990ffab64afeb4ea,
title = "Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis",
abstract = "BACKGROUND. The goals of the current study were to describe patterns of prostate specific antigen (PSA) surveillance for prostate carcinoma progression in a community-based cohort of patients and to identify independent clinical and socio-demographic factors that predict the frequency of surveillance. METHODS. Patients diagnosed with localized prostate carcinoma from October 1, 1991 to December 31, 1992 in New Haven and Hartford, Connecticut, were identified. Data were collected through standardized outpatient medical record review. Multivariate statistical methods were used to determine the factors that independently predicted the frequency of surveillance. RESULTS. Six hundred fifty-eight men with localized prostate carcinoma were included in the cohort. Forty-five percent of all patients were tested at least once annually, and 69{\%} were tested at least once every 2 years. Multivariate models indicated that African American men were half as likely as Caucasian men to receive annual testing (odds ratio [OR], 0.49; 95{\%} confidence interval [CI], 0.24-0.97). Men diagnosed at age 70 years or older were 38{\%} less likely to have annual testing than men diagnosed between the ages of 65 and 69 (OR, 0.62; 95{\%} CI, 0.41-0.94). A higher Gleason score and PSA at presentation also were associated independently with higher rates of annual PSA surveillance. CONCLUSIONS. Postdiagnosis PSA surveillance is common, although not universal. African American men were at significantly greater risk for receiving less frequent testing compared with Caucasian men. This disparity in access to care may explain, in part, previously observed racial differences in survival in prostate carcinoma. Further research is needed to identify the reasons for the racial disparity in PSA surveillance and to design interventions to lessen these differences.",
keywords = "Prostate carcinoma, Prostate specific antigen testing, Race, Recurrence, Surveillance",
author = "Zeliadt, {Steven B.} and Penson, {David F.} and Albertsen, {Peter C.} and John Concato and Ruth Etzioni",
year = "2003",
month = "8",
day = "1",
doi = "10.1002/cncr.11492",
language = "English (US)",
volume = "98",
pages = "496--503",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis

AU - Zeliadt, Steven B.

AU - Penson, David F.

AU - Albertsen, Peter C.

AU - Concato, John

AU - Etzioni, Ruth

PY - 2003/8/1

Y1 - 2003/8/1

N2 - BACKGROUND. The goals of the current study were to describe patterns of prostate specific antigen (PSA) surveillance for prostate carcinoma progression in a community-based cohort of patients and to identify independent clinical and socio-demographic factors that predict the frequency of surveillance. METHODS. Patients diagnosed with localized prostate carcinoma from October 1, 1991 to December 31, 1992 in New Haven and Hartford, Connecticut, were identified. Data were collected through standardized outpatient medical record review. Multivariate statistical methods were used to determine the factors that independently predicted the frequency of surveillance. RESULTS. Six hundred fifty-eight men with localized prostate carcinoma were included in the cohort. Forty-five percent of all patients were tested at least once annually, and 69% were tested at least once every 2 years. Multivariate models indicated that African American men were half as likely as Caucasian men to receive annual testing (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.24-0.97). Men diagnosed at age 70 years or older were 38% less likely to have annual testing than men diagnosed between the ages of 65 and 69 (OR, 0.62; 95% CI, 0.41-0.94). A higher Gleason score and PSA at presentation also were associated independently with higher rates of annual PSA surveillance. CONCLUSIONS. Postdiagnosis PSA surveillance is common, although not universal. African American men were at significantly greater risk for receiving less frequent testing compared with Caucasian men. This disparity in access to care may explain, in part, previously observed racial differences in survival in prostate carcinoma. Further research is needed to identify the reasons for the racial disparity in PSA surveillance and to design interventions to lessen these differences.

AB - BACKGROUND. The goals of the current study were to describe patterns of prostate specific antigen (PSA) surveillance for prostate carcinoma progression in a community-based cohort of patients and to identify independent clinical and socio-demographic factors that predict the frequency of surveillance. METHODS. Patients diagnosed with localized prostate carcinoma from October 1, 1991 to December 31, 1992 in New Haven and Hartford, Connecticut, were identified. Data were collected through standardized outpatient medical record review. Multivariate statistical methods were used to determine the factors that independently predicted the frequency of surveillance. RESULTS. Six hundred fifty-eight men with localized prostate carcinoma were included in the cohort. Forty-five percent of all patients were tested at least once annually, and 69% were tested at least once every 2 years. Multivariate models indicated that African American men were half as likely as Caucasian men to receive annual testing (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.24-0.97). Men diagnosed at age 70 years or older were 38% less likely to have annual testing than men diagnosed between the ages of 65 and 69 (OR, 0.62; 95% CI, 0.41-0.94). A higher Gleason score and PSA at presentation also were associated independently with higher rates of annual PSA surveillance. CONCLUSIONS. Postdiagnosis PSA surveillance is common, although not universal. African American men were at significantly greater risk for receiving less frequent testing compared with Caucasian men. This disparity in access to care may explain, in part, previously observed racial differences in survival in prostate carcinoma. Further research is needed to identify the reasons for the racial disparity in PSA surveillance and to design interventions to lessen these differences.

KW - Prostate carcinoma

KW - Prostate specific antigen testing

KW - Race

KW - Recurrence

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=0038299194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038299194&partnerID=8YFLogxK

U2 - 10.1002/cncr.11492

DO - 10.1002/cncr.11492

M3 - Article

C2 - 12879465

AN - SCOPUS:0038299194

VL - 98

SP - 496

EP - 503

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -